Brivaracetam Synthesis Using L-Menthol Resolution
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing methods for the preparation of brivaracetam are inefficient and do not effectively separate diastereomers, leading to impurities in the final product.
Innovation Solution
A process involving the reaction of a compound of formula VI with L-menthol to form compound IV, followed by reaction with (2S)-2-aminobutanamide to create a diastereomeric mixture, separation of desired and undesired diastereomers, and cyclization to obtain brivaracetam, using specific coupling reagents and solvents to enhance purity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing methods are used for preparation of brivaracetam, then the process is simpler, but the chemical purity and diastereomeric excess are low leading to impurities above 1%
Solution Approach 1:
The synthesis process is divided into distinct stages: resolution of racemic mixture to obtain pure (R)-intermediate, followed by stereoselective formation of diastereomers, and final separation of diastereomers. This segmentation allows each step to be optimized for purity while maintaining overall process feasibility.
Solution Approach 2:
L-menthol is used as a chiral resolving agent that forms diastereomeric intermediates with the racemic substrate. This intermediary step enables separation of enantiomers through diastereomer formation, which can then be resolved and converted to the desired pure stereoisomer.
2Manufacturing precision
If existing methods are used, then fewer separation steps are required, but impurities in the final product exceed 1%
Solution Approach 1:
The racemic mixture is resolved at an early stage to obtain pure (R)-intermediate before proceeding to diastereomer formation. This preliminary resolution prevents contamination of the final product with wrong enantiomers, ensuring high purity without requiring extensive purification later.
Solution Approach 2:
Different separation techniques are applied at different stages: chiral resolution for enantiomers, and diastereomer separation for the final step. Each separation is tailored to the specific requirements of that stage, optimizing purity while minimizing overall process complexity.
3Manufacturing precision
If conventional preparation methods are used, then the process is faster, but diastereomeric separation is ineffective leading to impurities
Solution Approach 1:
L-menthol forms diastereomeric intermediates that have different physical properties, enabling effective separation. This intermediary approach converts the difficult task of separating enantiomers into the easier task of separating diastereomers, which can be resolved by standard chromatographic or crystallization methods.
Solution Approach 2:
The physical and chemical parameters of the intermediate compounds are changed through diastereomer formation, creating compounds with different solubilities, polarities, and other properties that facilitate separation. This parameter change enables effective separation without requiring complex or time-consuming methods.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The process achieves high chemical purity and diastereomeric excess of brivaracetam, with impurities below 1%, ensuring a high-quality final product.
Implementation Method 1
reacting a compound of formula VI with L-menthol to obtain a compound of formula IV
Implementation Method 2
separating the desired diastereomer, a compound of formula IIA and the undesired diastereomer, a compound of formula IIB, from the diastereomeric mixture
Implementation Method 3
separating the desired diastereomer, a compound of formula IIA and the undesired diastereomer, a compound of formula IIB, from the diastereomeric mixture
Implementation Method 4
cyclizing the compound of formula IIA, to obtain brivaracetam, the compound of formula I
Data Source
AI summary
The present invention relates to a process for the preparation of brivaracetam, a compound of formula I and salts thereof. The present invention also relates to a compound of formula II and a compound of formula IIA, process for its preparation and conversion thereof to brivaracetam, the compound of formula I.